Cadent Therapeutics is rapidly advancing a pipeline of novel allosteric modulators of ion channels – taking a well-established pharmaceutical approach and stepping out into new territory. SK channels and NMDA receptors are ion channels that are critical for modulating the strength, timing, and integration of communication between and within neurons and neuronal networks in the central nervous system. But there are no approved drugs that are selective allosteric modulators of these ion channels. Cadent’s first-of-its-kind approach has the potential to provide new types of treatments for movement and cognitive disorders.
Our pipeline is rich with candidates rapidly advancing into the clinic.
MEET OUR TEAM
Learn more about the incredibly talented and fun group of individuals behind our mission.
To learn more about the cadence-1 clinical trial or Cadent Therapeutics, please contact us.